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Abstract
Direct molecular tests in blood for early Lyme disease can be insensitive due to low amount of circulating Borrelia
burgdorferi DNA. To address this challenge, we have developed a sensitive strategy to both detect and genotype B.
burgdorferi directly from whole blood collected during the initial patient visit. This strategy improved sensitivity by
employing 1.25 mL of whole blood, a novel pre-enrichment of the entire specimen extract for Borrelia DNA prior to a multi-
locus PCR and electrospray ionization mass spectrometry detection assay. We evaluated the assay on blood collected at the
initial presentation from 21 endemic area patients who had both physician-diagnosed erythema migrans (EM) and positive
two-tiered serology either at the initial visit or at a follow-up visit after three weeks of antibiotic therapy. Results of this DNA
analysis showed detection of B. burgdorferi in 13 of 21 patients (62%). In most cases the new assay also provided the B.
burgdorferi genotype. The combined results of our direct detection assay with initial physician visit serology resulted in the
detection of early Lyme disease in 19 of 21 (90%) of patients at the initial visit. In 5 of 21 cases we demonstrate the ability to
detect B. burgdorferi in early Lyme disease directly from whole blood specimens prior to seroconversion.
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Introduction
Lyme disease, caused by the tick-borne bacteria Borrelia
burgdorferi, is the most commonly reported vector-borne infectious
disease in North America. The number of yearly cases reported to
the CDC has steadily increased since 1982 when case reporting
began, with 20,000–30,000 cases now reported each year [1,2].
If promptly diagnosed and correctly treated, outcomes for early
Lyme disease are generally considered to be excellent. Direct
Borrelia molecular tests, such as PCR, from blood can detect and
identify active infection sooner than serologic tests but typically
these tests have suffered from low assay sensitivity for clinical use.
For example early studies using PCR to detect Borrelia in the blood
during active infection had limited success with sensitivities of only
18.4% and 26.1% [3,4]. Studies in recent years have reported
a higher detection rate down to 10 genome copies through
sampling larger blood volumes, in some cases culturing prior to
PCR, and by using different PCR techniques such as qPCR or
nested PCR [5,6,7].
In the past, PCR assays for Lyme disease did not have the
benefit of current advances in sample preparation [8] or target
DNA amplification techniques that could enable the detection of
single digit copy numbers of Borrelia DNA in large volume samples.
Studies have shown PCR detection of B. burgdorferi can be
enhanced by culturing the specimen in growth medium prior to
PCR indicating the presence of organism below the limits of
detection by PCR [6].
We have previously applied broad-range PCR and electrospray
ionization mass spectrometry (PCR/ESI-MS) for the detection of
vector-borne pathogens such as Ehrlichia, Powassan virus, and
canine heartworm [9,10,11]. The basis of this detection and
identification is a multi-locus broad range PCR followed by the
determination of the mass of the amplicons using automated
electrospray ionization mass spectrometry. From the masses of the
amplicons, the numbers of DNA base pairs A’s, G’s, C’s and T’s in
each amplicon are determined. By analysis of the base composi-
tions of amplicons from all primer pairs, the organisms present in
the sample can be identified from a database of all known base
count signatures and quantified [12,13]. This technique has the
advantage of rapidly identifying pathogens, genotyping pathogens
and can identify new genetic variants. To address the need for
a better test for early Lyme disease we have improved the
sensitivity of PCR/ESI-MS by the use of 1.25 mL of whole blood
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e36825and an isothermal amplification (IA) for Borrelia DNA on the entire
specimen extract prior to a multi-locus PCR/ESI-MS assay.
Methods
Ethics Statement
The study was approved by the Johns Hopkins Medicine
Institutional Review Board. Written informed consent was re-
ceived from participants prior to inclusion in the study.
Early Lyme disease patient specimens
A set of 29 whole blood samples including pretreatment (acute)
and post-treatment (convalescent) samples were obtained and
analyzed from consecutively enrolled adult patients from an area
endemic for Lyme disease (Baltimore and adjacent counties of
Maryland) and not know to be endemic for STARI. Patients
presented in the spring and summer of 2009 with a rash consistent
with EM and systemic symptoms consistent with an acute B.
burgdorferi infection such as general malaise, headache, and the ‘flu-
like’ symptoms. These patients had been referred to a primary care
physician with infectious disease training (JA) and previous
experience identifying EM in research settings [14]. The initial
samples were obtained prior to initiating a three week course of
doxycycline antibiotic therapy. Patients with a prior history of
Lyme disease or symptom duration of their current illness of
longer than 3 months or a history of chronic illnesses associated
with immune suppression or chronic functional somatic disorders
were excluded. To ensure our sample cohort was infected with B.
burgdorferi and did not just present with an EM-like rash due to
other causes, all patients, in addition to a clinical diagnosis, were
required to have laboratory evidence of infection by 2-tiered
serological testing following CDC testing guidelines for acute and
convalescent testing [15]. Of the 29 initial patients with EM and
clinical symptoms, 21 also had serologic evidence of exposure to B.
burgdorferi infection and are the focus of this report.
Endemic area negative control specimens were procured from
Biomed Supply Inc. (Carlsbad, CA). Paired whole blood and
serum specimens were collected December 2010 from a total of 44
healthy donors at a donation site in Pennsylvania for the molecular
and serological testing.
Serological and other analyses
At the initial, pre-treatment study visit 2-tiered antibody testing
for B. burgdorferi were performed on the patient’s serum sample as
part of the patient clinical evaluation. Patients with negative 2-
tiered results were tested again following the three week antibiotic
treatment period in a follow-up study visit. All serologic testing for
both the patient specimens and the negative controls was
performed through the same commercial laboratory using
standardized protocols. Results were interpreted according to
CDC reccommendations for test interpretation for Lyme disease
[15].
DNA extraction from blood specimens
A combination of bead-beating and magnetic bead isolation was
used to extract nucleic acids from 1.25 mL of whole EDTA blood.
The blood was mixed in 2.0 mL screw-cap tubes (Sarstedt,
Newton NC) filled with 1.35 g of 0.1 mm yttria-stabilized
zirconium oxide beads (Glen Mills, Clifton, NJ), 25 mL Proteinase
K solution (Qiagen, Valencia, CA), 142 mL of 20% SDS solution
(Ambion, Austin, TX) and 1 mL of DNA extraction control
(Abbott Molecular, Des Plains, IL). The mixture was then
homogenized in a Precellys 24 tissue homogenizer (Bioamerica
Inc., Miami, FL) at 6,200 rpm for 3 sets of 90 sec with 5 sec
between sets. The homogenized lysates were then incubated at
56uC for 15 min and then centrifuged for 3 min at 16,000 g in
a bench top microcentrifuge. To isolate nucleic acids 1 mL of the
supernatant was transferred to a 24-well deep-well Kingfisher plate
(Thermo Scientific, Waltham, MA) along with 1.1 mL of Abbott
lysis buffer (Abbott Molecular), and 160 mL of magnetic particles
(Abbott Molecular). The plate was then used on a Kingfisher Flex
(Thermo Scientific) to automate binding, washing, and elution of
the nucleic acids. The specimens were incubated for 16.5 minutes
in the lysis buffer at 56uC. Specimens were then washed once in
Wash buffer I (Abbott Molecular), and three times in Wash buffer
II (Abbott Molecular), with 1 min incubation for each wash step.
The magnetic beads were then dried for 3 min at 65uC, and
nucleic acids were eluted into 250 mL of elution buffer (Abbott
Molecular), by incubating the magnetic particles at 65uC for
3 min.
Isothermal amplification of B. burgdorferi target DNA
Each of the seven target loci were amplified using 50
oligonucleotide primers flanking the locus (Table S1). The
primers were purchased in 96 well plates (IDT DNA, Ames, IA)
at a 1 mM conc and mixed in equal proportions to create a 1 mM
primer pool in tris EDTA buffer. Primers were designed using B.
burgdorferi B31 genome sequence (gi|15594346) with a GC content
of 25 to 50%, spaced 6–10 nucleotides apart with a target TM of
52uC. The pooled primers were dialyzed twice for 4 hours at 4uC
against a 4L solution containing 10 mM Tris pH 8.0 and 50 mM
EDTA pH 8.0 using a 5 mL Float-A-Lyzer G2 with a 0.5–1 kDa
MW cutoff (Spectrum Laboratories, Rancho Dominguez, CA).
Multiple primer isothermal amplification (IA) was performed in
a in a 0.6 mL PCR tube (Axygen Inc., Union City, California)
containing 200 mL of nucleic acid extract, 22.5 ml Ibis 10X PCR
Buffer II (Ibis Biosciences, Carlsbad, CA) [13], 0.2 mM dNTPs
Figure 1. B. burgdorferi detections with untreated and IA
treated whole blood extracts spiked with B. burgdorferi
genomic DNA. Nucleic acid extracts from 1.25 mL of whole blood
were spiked with decreasing of amounts of B. burgdorferi genomic DNA.
In duplicate, specimens were either untreated or underwent IA before
use in the PCR/ESI-MS B. burgdorferi detection/genotyping assay. The
number of primer pairs in the assay detecting B. burgdorferi DNA was
recorded for each specimen.
doi:10.1371/journal.pone.0036825.g001
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incubated at 95uC for 10 min followed by a cooling to 56uCi n
a MJ Thermocycler (Bio-Rad Laboratories, Hercules, CA.). 11.25
U of Bst DNA polymerase, Exonuclease minus (Lucigen,
Middleton, WI) enzyme was added to the reactions and they
were incubated at 56uC for 2 hours followed by an 80uC heat
inactivation for 20 min. The resulting reaction was used directly in
the subsequent PCR without purification.
Molecular detection and genotyping of B. burgdorferi
from whole blood from patients with clinically diagnosed
early Lyme disease
Borrelia was detected and genotyped by processing 2 mLo f
Borrelia enriched nucleic acid extracts per PCR reaction on
a previously described broad-range PCR/ESI-MS Borrelia geno-
typing assay that targets eight different loci in the Borrelia genome
[16]. Amplicons were analyzed using the research use only PLEX-
ID system (Abbott, Des Plaines, IL). When all eight primers
produced amplicons, a genotype of the Borrelia was determined as
previous described [16]. Detection of a Borrelia amplicon from one
or more of the eight primer pairs in the assay was used to positively
identify Borrelia DNA in a specimen.
Statistical analysis
The 95% confidence interval of our PCR positive blood
specimens undergoing IA/PCR/ESI-MS was calculated using the
modified Wald method which is useful when calculating from
a small sample size [17]. This method was also used on calculating
the 95% confidence interval for the combined assay approach.
Comparison of the specimens that were treated with IA verses no
treatment was performed using the McNemar’s exact test using R
for the analysis (www.r-project.org).
Results
Early Lyme disease patients
Of the 29 patients with clinically diagnosed EM, 21 also had
laboratory evidence of B. burgdorferi exposure by a positive two-
tiered serology test either on the initial physician visit or the follow-
up visit three weeks later. These 21 patients were included in the
study cohort and downstream analysis. (Table S2).
Improved PCR/ESI-MS sensitivity by Isothermal
Amplification
To detect the low levels of Borrelia genomic DNA in whole blood
samples from early Lyme disease patients we developed an
isothermal amplification (IA) assay that amplifies the seven B.
burgdorferi target regions used with a previously described Borrelia
broad-range PCR electrospray ionization mass spectrometry
detection and genotyping assay (PCR/ESI-MS)[16]. The strategy
behind this approach uses a combination of a strand-displacing
DNA polymerase in conjunction with multiple primers to
selectively amplify the target region in an isothemeral reaction.
The use of multiple primers flanking the target sequence allows
outer primers to displace the DNA strands created by inner
primers allowing the newly displaced strand to function as
a template for further amplification in a manner similar to
multiple displacement amplification [18]. The IA assay was
designed to specifically work with the entire output of DNA
extraction from 1.25 mL of whole EDTA blood to ensure
amplification of low levels of Borrelia DNA that may be present
in the specimens. The Borrelia enriched DNA can then be used
directly in the PCR/ESI-MS assay without any purification. Since
the IA is coupled with PCR/ESI-MS specificity for the target
detection is maintained through the PCR/ESI-MS. Using extracts
from 1.25 mL of human blood spiked with various amount of
quantified B. burgdorferi DNA (Barbara J. Johnson CDC, Fort
Collins, CO) (200 genome copies down to 0.3 genome copies) we
compared the sensitivity of the PCR/ESI-MS assay to detect B.
burgdorferi with and without the IA B. burgdorferi DNA enrichment
(Figure 1). Detection was determined when one or more of the
eight primers detected B. burgdorferi. As shown in Figure 1,
samples that were not enriched (neat) reproducibly detected down
to 200 B. burgdorferi genomes. When the IA B. burgdorferi DNA
enrichment was employed the sensitivity was reproducibly
improved down to 0.6 genomes. This demonstrated the IA B.
burgdorferi DNA enrichment process resulted in over a 200-fold
increase in sensitivity in the PCR compared to untreated.
The ability of IA to increase detection sensitivity in actual blood
specimens from patients was also evaluated. Blood extract from
the 21 early Lyme disease patients was extracted in duplicate. One
replicate underwent IA B. burgdorferi DNA enrichment prior to
PCR/ESI-MS while the other remained untreated. Each replicate
was then run on the PCR/ESI-MS assay. In the untreated samples
we detected B. burgdorferi in two of the 21 patients. In the IA B.
burgdorferi DNA enriched samples we detected B. burgdorferi in 13 of
the patient samples. When comparing samples from the same
patient that were processed with and without IA using the
McNemar’s exact test, IA provided a significantly higher rate of
detection (P=0.001). This finding demonstrates that the use of our
isothermal amplification prior to PCR can significantly improve
the sensitivity of the PCR based assays.
Molecular detection of Borrelia burgdorferi from whole
blood by isothermal amplification, PCR/ESI-MS, and two-
tiered serology
The IA/PCR/ESI-MS assay detected B. burgdorferi in 13 of 21
patient specimens (62% with a 95% confidence interval of 40%-
79%) while two-tiered serology was positive in 14 of the 21
specimens (67% with a 95% confidence interval of 45%-83%) at
the initial diagnostic pre-treatment visit Table 1. Of the 44
control patient sera, a single sample was seropositive by ELISA
and IgG western blot, but all control specimens were IA/PCR/
ESI-MS negative (Table 1). This low rate in seropositivity in our
sample set from the eastern United States is consistent with the
known background seroreactivity expected from remote exposure
in an endemic region [19,20].
Table 1. Comparison of isothermal amplification PCR/ESI-MS
assay and two-tier serology for the detection of early Lyme
disease on initial patient visit.
Early
two-tier
Serology
Pos Neg Total
Early Lyme Disease IA/PCR/ESI-MS + 851 3
IA/PCR/ESI-MS - 6 2 8
Total 14 7 21
Control group IA/PCR/ESI-MS + 000
IA/PCR/ESI-MS - 1 43 44
Total 1 43 44
doi:10.1371/journal.pone.0036825.t001
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IA/PCR/ESI-MS assay, 5 were negative by the 2-tiered test at the
first physician visit (Table 2). the 8 patients negative by the IA/
PCR/ESI-MS, 6 were positive by serology on initial visit and the
remaining 2 where found positive by serology on the follow-up
physician study visit (Table 2).
Examining the ability to detect B. burgdorferi infection in patients
with early Lyme disease at the initial physician visit with either
laboratory test, IA/PCR/ESI-MS or two-tiered serology, resulted
in 19 of 21 patient specimens (90% with a 95% confidence interval
of 70% to 99%) having a positive detection of B. burgdorferi
infection.
Genotyping of B. burgdorferi from patients with early
Lyme
The eight primer pairs used in the IA/PCR/ESI-MS assay have
been previously used to genotype B. burgdorferi [16]. A combination
of the basecount signatures from the 8 loci can provide genotyping
of B. burgdorferi at a similar if not higher level of resolution
compared to ospC typing. Of the 14 IA/PCR/ESI-MS positive
specimens 9 specimens detected B. burgdorferi with all eight primers
thus producing a genotype [16]. Of these specimens two were
positive with genotype 6 and two specimens were positive with
genotype 7 [16]. Four specimens were positive with genotypes 1,
10, 22 and 33. One specimen produced a previously unseen
genotype and was designated genotype 76 (Table 2). This new
genotype is similar to the previously seen genotype 14 except the
basecount signatures for primer pairs BCT3516 was
A38G28C24T38 and BCT3518 was A38G22C14T36.
Discussion
Our results demonstrate an improved strategy for detecting B.
burgdorferi infection from whole blood in patients with erythema
migrans and acute Lyme disease. Employing isothermal amplifi-
cation of DNA prior to PCR, we were able to detect the low
numbers of organisms often associated with blood stream invasion
in early Lyme disease. For this initial study the choice of patients
with early untreated Lyme disease was important because of the
known relationship of EM with acute infection and the published
rates of bacteremia in this setting using Borrelia culture [21]. The
ability to confirm early infection with direct pathogen based tests
has significant research applications and the potential future
clinical application of DNA based diagnosis.
The development of pathogen based diagnostic tests in Lyme
disease is important because the only objective clinical finding that
can be used to diagnose Lyme disease, the EM, is subjective in
interpretation and can result in false positive and false negative
diagnosis [22]. The identification of EM is further limited by the
variability in the appearance of the skin lesion creating the
potential for clinical misdiagnosis [23]. The most common current
laboratory tests for Lyme disease, two-teired serology, can also
provide false positive or negative results due to variations in the
immune response of the patient. Because of the biologically
delayed antibody response in the initial 3 weeks of infection, the
sensitivity of serological tests may be as low as 40% [24,25]. False
positive tests can occur with IgM immunoblots and a positive IgG
immunoblot cannot distinguish active infection from past expo-
sure.
Since the adoption of the current two-tier serologic based test
for Lyme disease surveillance there have been few practical
alternative diagnostic tests available to the clinician. The ability to
culture B. burgdorferi has been important for use in research
applications to confirm the diagnosis of B. burgdorferi infection, but
is not available or practical for use in a clinical setting because it
requires weeks before cultures become positive. Past attempts at
PCR diagnosis for North American Lyme disease with blood
samples has been largely unsuccessful due to the low sensitivity
[3,4]. European researchers have reported varying rates of success
using PCR to detect members of the B. burgdorferi s.l. group from
blood or its components; 7.5% up to 78.1% [26,27,28]. The
difficulty of detecting Lyme Borrelia in the blood has been
attributed to the low numbers of organisms circulating in the
blood stream in acute infection [7,14,29]. In recent studies in
North America, using larger blood volumes in addition to utilizing
more sensitive nested PCR tests have had increased success in
detecting the low densities of Borrelia that are typically present in
the blood in early Lyme disease [6,7]. These studies also
demonstrated that a direct detection strategy can work provided
enough blood is examined and the assay is sensitive down to
genome copies numbers in the 10–100 range.
To overcome the challenge of extremely low density of
spirochetes in the blood and increase assay sensitivity we utilized
a combination of strategies. By using a relatively large volume of
whole blood we increased the probability of B. burgdorferi DNA
being present in the specimen. Next, the IA strategy developed
here enriches the entire nucleic acid extract for Borrelia DNA prior
to PCR thereby increasing the probability that any Borrelia DNA
present is detected. Lastly we used a mass spectrometry-based
multi-locus assay to increase the number of possible targets in the
Borrelia genome we may detect. Extracts subjected to IA can also
be used to screen for other pathogens without affecting the
sensitivity of the individual assays (data not shown). All of the
specimens in the study were tested for other tick-borne pathogens
including Babesia, Anaplasma, Ehrlichia and no co-infections were
found (data not shown). A key technical development of the
isothermal amplification is that it uses the entire output of a whole
blood DNA extraction and employs a set of 50 primers per target
locus (350 primers total) to assure amplification of the B. burgdorferi
target loci even the presence of high levels of human DNA. The
isothermal amplification is a relatively simple addition to a PCR
assay work flow and this approach could be applied to other assays
Table 2. Specimen results for IA/PCR/ESI-MS, initial, and follow-up two-tiered serology testing.
# patients # with Muliple EM IA/PCR/ESI-MS Early two-tier serology
Follow-up two-tier
serology Genotype Found
8 6 Pos Pos ND 6, 6, 7, 22, 33
5 1 Pos Neg Pos 1, 10, 76
6 4 Neg Pos ND ND
2 0 Neg Neg Pos ND
doi:10.1371/journal.pone.0036825.t002
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the limits of detection by PCR. Furthermore the method should be
applicable to DNA extracts from a variety of specimen types such
as tissue, cerebrospinal fluid, serum, plasma or synovial fluid.
The IA approach combined with the Borrelia PCR/ESI-MS
genotyping assay not only has the ability to detect extremely low
genome copies of B. burgdorferi in a specimen, it is also able to
identify the specific genotype of the infecting B. burgdorferi. When
the IA/PCR/ESI-MS assay detects Borrelia with all eight primer
pairs a multi-locus genotype can be determined [16]. From our set
of 13 positive specimens 9 produced a full genotype representing
seven unique genotypes (genotypes 1, 6, 7, 10, 22, 33 and 76) [16].
Earlier studies have indicated some strains may be associated with
a propensity to disseminate and perhaps to specific organ systems
[30]. Had we been able to perform skin biopsies in the subjects, we
may have been able to ascertain which blood PCR negative
subjects were skin PCR positive and had a genotype that appeared
to be skin-restricted. Future studies which examine both skin
biopsies and blood in patients with early Lyme disease could
examine which infecting Borrelia genotypes might be restricted to
the skin and which genotypes have the ability to disseminate into
the blood stream and other tissues.
Comparison of IA/PCR/ESI-MS and 2-tier serologic testing
showed that the IA/PCR/ESI-MS based method was able to
identify patients early in the course of infection at a time when
many had not yet developed a diagnostic humoral immune
response. Five of the IA/PCR/ESI-MS positive specimens were
negative by the 2-tier test on the initial physician visit. When
retested at visit two, 3 weeks later, all had evidence of
seroconversion indicating acute exposure. Results of this analysis
showed detection of early Lyme disease in 13 patients (62%). In
one of the 8 patients excluded from the cohort due to not having
a positive two-tiered serology test that met CDC guidelines we
detected B. burgdorferi DNA with the IA/PCR/ESI-MS assay
(specimen # 9, Table S2). While this patient was not part of the
21 patients in the cohort due to negative serology test results, this
sample did show increased sero-reactivelty at the follow-up two-
tier test and most likely represented a Borrelia positive patient with
a weak serologic response. The combined results of our direct
detection assay with initial physician visit serology resulted in the
detection of 19 of 21 (90%) of patients at the initial visit.
The IA/PCR/ESI-MS assay can be performed in 8 hours and
can detect B. burgdorferi in early Lyme disease prior to serocon-
version, indicating the presence of an active infection. This
distinguishes our assay from traditional serological tests, which
cannot differentiate active infection from prior exposures. A recent
study examining paired samples of skin biopsies and blood found
that of 249 patients with positive skin biopsy cultures only 108
(43.4%) had positive blood cultures [31]. This is similar to our
results detecting B. burgdorferi in the blood of 62% of patients with
an EM rash and could point to a limitation based upon the true
biologic rates of bacteremia with early B. burgdorferi infection and
not assay sensitivity [21]. When positive, the IA/PCR/ESI-MS
assay can provide an immediate early and unambiguous result in
a single test without the need for a later second visit convalescent
sample as with serology. Additionally the genotype information
provided may give insight into the pathogenicity or biologic
behavior of the infecting strain that can be explored in larger
studies. The application of our IA/PCR/ESI-MS assay for use in
specific clinical settings warrants further study with defined
diagnostic criteria to assess its clinical applicability [32]. One such
example would be a study in high risk patients with ‘‘summer flu-
like’’ illness in endemic areas for Lyme disease. Many other blood-
borne infections may contain low levels of circulating pathogen
DNA and would also benefit from the IA approach to improve
PCR sensitivity.
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